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Hyperleukocytosis is a medical emergency and is
defined as peripheral blood leukocyte count exceeding
100x109/L. Acute hyperlukocytic leukemia (AHL) is
reported in 5-22% of children at diagnosis with mortality
rate 4-24%.1-4 Ischemic complications of hyperleukocytosis
are related to leukostasis in brain and lung with
metabolic complications related to tumor lysis syndrome
(TLS).1 There were only a few published reports on hyper-
leukocytosis in children.5 The data on hyperleukocytic
leukemia in children from Pakistan is scarce. The aim of
this study was to report frequency, severity, clinical
presentation, treatment and short-term outcome of all
children with AHL in two pediatric oncology centers in
Karachi.
Medical records of all eligible participants were retro-
spectively reviewed to collect the pertinent demographic,
clinical and outcome data on structured data collection
sheet from 2009 to 2015, after approval from ethical
review committee (1234-Peds-ERC). The cohort of AHL
was divided into two groups, based on the WBC counts:
(Group I - 100-199, Group-II - >200 x109/L); primary
outcome (group 1 - alive, group II - expired).
The secondary outcomes were defined as occurrence of
complications that occurred during the first 14 days after
presentation as described by Lowe et al.5 Pulmonary
leukostasis syndrome was defined as the triad of
infiltrate on CXR, tachypnea and hypoxia. Neurological
event was defined as any neurological complications
that met the National Cancer Institute criteria.5 Tumor
lysis syndrome (TLS) was defined as either laboratory
TLS (LTLS) or clinical TLS (CTLS). LTLS was defined as
presence of at least two of the features, namely
hyperurecemia (serum uric acid >8mg%), hyper-
phosphotemia (serum phosphorus >6.5mg%), hyper-
kalemia (serum potassium >6meq/l), and hypo-
calcaemia (serum calcium <7 mg%). CTLS required the
presence of LTLS in addition either one of the three
clinical complications, namely renal dysfunction,
arrhythmias, features of leukostasis (seizure/intracranial
bleed and/or priapism).2
After establishing diagnosis of acute hyperleukocytic
leukemia, all patients received standard treatment
including hyperhydration, allopurinol, cytoreduction and
organ-supportive care, as needed. Cytoreduction
therapy was performed at the discretion of attending
pediatric oncologist. Decision to perform leukapheresis
was based on a multidisciplinary team consensus
including oncologist, intensivist, and hematologist.
The overall frequency of pediatric oncology patients,
who presented with hyperleukocytosis (>100 x109/L)
during the study period, was determined by dividing the
number of admissions to pediatric oncology patients with
hyperleukocytosis with the total number of admissions to
the pediatric oncology unit. For analysis, SPSS version
20 (IBM, Chicago, USA) was used. Frequencies with
percentages were computed for qualitative variables
and mean SD and median (IQR) were computed for
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ABSTRACT
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quantitative variables depending whether the data was
distributed evenly or skewed, respectively. The risk
factors associated with hyperleukocytosis (100-200 x
109/L) and for increased mortality was calculated with
Chi-square test for categorical variables and
independent t-test used for continuous variables, with
p-value < 0.05 was considered significant.
During the study period, 1,045 patients were diagnosed
as acute leukemia and 13.97% (146/1045) had
hyperleukocytosis at presentation. Majority (94.5%,
n=138) of these patients were diagnosed as ALL, of
which 44.5% (n=65) had extreme hyperleukocytosis
(<200 x109/L). Patients’ demographics, clinical and
laboratory characteristics are summarized in Table I. The
initial median WBC was 181 x109/L (IQR, 130.45-
298.3). The overall incidence was high in age group
between 1-10 year (61.7%, 90/146) with male
preponderance (76%, 111/146). Duration of illness was
>30 days in nearly 50% of patients, indicating late
presentation. Majority (74.6%, n=109) patients developed
one or more complications in this cohort with infectious
complications being the most common (45.2%, n=66).
Laboratory TLS developed in 39% (n=57) and clinical
TLS was observed in 17.1% (n=25), respectively. The
complications related to leukostasis were observed in
2.7% (n=4), 24.6% (n=36) and 22.6% (n=33) as isolated
neurological and isolated pulmonary complications and
combined neuro-pulmonary complications, respectively.
The intensive-care resources were utilized in 26%
(n=38), with 20.5% (n=30) and 4.1% (n=6) patients
requiring vasoactive-inotropic support for hemodynamics
plus mechanical ventilation and mechanical ventilation
alone, respectively. Four patients (2.7%) required
leukapheresis as a short-term cyoreductive intervention
in conjunction with other therapies. Only one patient
required intermittent hemodialysis for acute kidney injury
due to clinical TLS. The case-specific mortality in this
cohort was 20.5% (n=30). Cytogenetic studies were
performed on 90 patients and translocations were
identified in 18 patients, involving BCR-ABL (9.6%,
n=14), MLL gene rearrangement (2.1%, n=3) and Tel
AML 1 (2.7%, n=1).
When comparing hyperleukocytosis with extreme
hyperleukocytosis, we found significant differences in
uric acid, serum potassium and serum creatinine (Table I).
When comparing the outcome of patients with
hyperleukocytosis in terms of alive or expired, we found
need of vasoactive-inotropic support for hemodynamics
plus mechanical ventilation, infectious, respiratory and
CNS complications significantly associated with
increased mortality (Table II).
This is the first comprehensive report on children with
hyperleukocytic acute leukemia presenting at two major
pediatric cancer centers of Karachi, Pakistan. Few
studies have been published on clinical profile and
outcomes of children with acute leukemia in children
from Pakistan.6 The frequency of hyperleukocytosis was
14% with two-thirds of children being less than 10 years
of age, which is similar to other reports.2-5 Majority were
males (76%, n=111), similar to Lowe et al in which 64%
were found to be males.5 Half of the patients in this study
had duration of illness of more than 30 days before
presentation, which represent late recognition and
referrals, resulting in delayed diagnosis. This may lead
to progression of disease, development of complications
and poor outcome in children with cancer. Most of
children 94.5% (n=138) had acute lymphoblastic
leukemia in this cohort as compared to 14.5% in the
report of Bakhshi et al.2 Hyperleukocytosis was seen
more in patients with T-cell ALL (50.9%), which is
consistent with other pediatric reports.3,4
In this study, the rate of complications of leukostasis
(both neurological and pulmonary) were similar to other
published reports in literature.2 Only one patient
presented with priapism in this study, which did not
require any urological surgical intervention. Both clinical
and laboratory TLS were observed in one-quarter of
patients as reported by Kulkarni et al.4 Hyperuricemia
was the most common metabolic abnormality (32.2%,
n=47) observed, which is related to rapid destruction of
leukemic blast cell that results in acute renal
dysfunction. However, only one patient required
intermittent hemodialysis for brief duration. The
frequency of pulmonary and neurological insults,
secondary to leukostasis in children with acute leukemic
hyperleukocytosis, varies from 4% to 20% in different
pediatric reports.2,3 Recently, Kong et al. reported 10%
and 4% of neurologic and pulmonary complications in
their cohort of childhood acute lymphoblastic leukemia
with hyperleukocytosis, respectively.4 Lowe et al.
reported 6% and 9% of neurologic and pulmonary
injuries due to leukostasis in their cohort, respectively.
However, there was no difference in the incidence of
pulmonary complications between two groups. Most of
the presently reported patients required only hyper-
hydration, allopurinol and chemotherapy along with
intense monitoring. The leukapheresis was done only in
4 cases without any complication. Despite being
invasive, this procedure is a safe and effective if
performed by experienced staff.
A very high frequency of infection-related complications
was observed during the induction-remission phase,
consistent with the fact that sepsis has been identified
as a major cause of morbidity and mortality in children
with cancer. This highlights the importance of education
and training in preventing, recognizing and treating
infections in such high-risk group. 
The mortality rate was 20.5% (n=30) in this cohort. The
early mortality in children with hyperleukocytic acute
leukemia has been reported to be 4% to 27%.2-5 There
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Table I: Patients' characteristics of acute hyperleukocytic leukemia.
Characteristics All 100,000-200,000 >200,000 p-value RR
N=146 (%) N=81 (%) N=65 (%) (95% CI)
Age
1-10 years 90 (61.7%) 50 (61.7%) 40 (61.7%) 0.068 -
>10 years 56 (38.4%) 31 (38.3%) 25 (38.5%)
Gender
Male 111 (76%) 61 (75.3%) 50 (76.9%) 0.848 0.915
Female 35 (24%) 20 (24.7%) 15 (23.1%) (0.425-1.970)
Diagnosis
Pre B cell ALL 61 (41.8%) 40 (49.4%) 21 (32.3%) 0.156 -
T cell ALL 77 (52.7%) 38 (46.9%) 39 (60%)
AML 5 (3.4%) 2 (2.5%) 3 (4.6%)
CML 3 (2.1%) 1 (1.2%) 2 (3.1)
Duration of illness before diagnosis
1-10 days 26 (17.8%) 13 (16.0%) 13 (20%) 0.858 -
10-30 days 48 (32.9%) 27 (33.3%) 21 (32.3%)
>30 days 72 (49.3%) 41 (50.6%) 31 (47.7%)
CNS 
I 127 (87%) 68 (84%) 59 (90.8%) 0.067 -
II 2 (1.4%) 0 (0%) 2 (3.1%)
III 17 (11.6%) 13 (16%) 4 (6.1%)
Therapeutic Intervention
Hydration + Steroids 138 (94.5%) 78 (96.3%) 60 (92.4%) 0.065 -
Hydration + Steroids + Leukapheresis 3 (2.1%) 0 (0%) 3 (4.6%)
Others 5 (3.4%) 3 (3.7%) 2 (3%)
ICU Interventions
Mechanical Ventilation 6 (4.1%) 1 (1.2%) 5 (7.7%) 0.106 -
Mechanical Ventilation + Inotropes 30 (20. 5%) 15 (18.5%) 15 (23.1%)
Mechanical Ventilation + Inotropes + RRT 1 (0.7%) 0 (0%) 1 (1.5%)
Inotropes 1 (0.7%) 1 (1.5%) 0 (0%)
None 108 (74%) 64 (79%) 44 (67.7%)
Laboratory Data
Hemoglobin (mg/dl) mean (+/- SD) 7.44  (2.38) 7.1 (+/-2.51) 7.83 (+/-2.16) 0.071 -0.720
(-1.482-0.073)
WBCs (/cmm) median (IQR) 181 (130-298) 132.6 (117.1-163.7) 310.7 (243-404) <0.001 -
Platelets (/cmm) median (IQR) 30 (18-60) 31 (18-54.5) 29 (19.5-65.5) 0.516 -
LDH (IU/L) median (IQR) 3184 (1681-6347) 2668 (1313-5704) 3517 (2193-7005) 0.289 -
Uric Acid (mg/dl) median (IQR) 5.9 (3.97-9.2) 5.19 (3.47-7.4) 7.31 (4.68-11.57) 0.002 -
Potassium (meq/L) mean (+/- SD) 4.03 (±0.75 3.86 (+/-0.57) 4.23 (+/-0.89) 0.004 -0.371
(-0.623- -0.119)
Phosphorus (mg/dl) mean (+/- SD) 4.3 (±2.02) 4.11 (+/-1.39) 4.51 (+/-2.53) 0.269 0.459
(-1.107-0.310)
Calcium (mg/dl) mean (+/- SD) 8.9 (±0.91) 8.9 (+/-0.89) 9.0 (+/-0.95) 0.822 0.036
(-0.355-0.282)
Creatinine (mg/dl) median (IQR) 0.6 (0.5-0.8) 0.60 (0.47-0.77) 0.63 (0.54-0.98) 0.028 -
Complications
Respiratory 49 (33.6%) 24 (29.6%) 25 (38.5%) 0.293 0.674
(0.338-1.344)
CNS 14 (9.6%) 3 (3.7%) 11 (16.9%) 0.189
(0.050-0.709)
Infectious 66 (45.2%) 38 (46.9%) 28 (43.1%) 1.168
(0.605-2.252)
Renal 32 (21.9%) 14 (17.3%) 18 (27.7%) 0.546
(0.247-1.204)
Outcome
Alive 116 (79.5%) 66 (81.5%) 50 (76.9%) 0.541 1.320
Dead 30 (20.5%) 15 (18.5%) 15 (23.1%) (0.590-2.951)
ALL = Acute lymphoblastic Leukemia;   AML = Acute Myeloginous Leukemia;   CML = Chronic Myeloginous Leukemia;   CNS = Central Nervous System;   ICU = Intensive Care Unit;   RRT = Renal
Replacement Therapy;   WBC = White Blood Cells;   LDH = Lactate Dehydrogenase.
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Table II: Risk factors of mortality among hyper leukocytosis patients.
Characteristics Alive Expired P-value RR
N=116 (%) N=30 (%) (95% CI)
Age
1-10 years 73 (62.9%) 17 (56.7%) 0.345 -
>10 years 43 (37.1%) 13 (43.3%)
Gender
Male 90 (77.6%) 21 (70%) 0.472 1.484
Female 26 (22.4%) 9 (30%) (0.606-3.629)
Diagnosis
Pre B cell ALL 49 (42.2%) 12 (40) 0.728 -
T cell ALL 59 (50.9%) 18 (60%)
AML 5 (4.3%) 0 (0%)
CML 3 (2.6%) 0 (0%)
Duration of illness before diagnosis
1-10 days 21 (18.1%) 5 (16.7%) 0.858 -
10-30 days 37 (31.9%) 11 (36.7%)
>30 days 58 (50%) 14 (46.7%)
CNS 
I 104 (89.7%) 23 (76.7%) 0.022 -
II 2 (1.7%) 0 (0%)
III 10 (8.6%) 7 (23.3%)
Therapeutic Intervention
Hydration + Steroids 109 (94%) 29 (96.7%) 0.849 -
Hydration + Steroids + Leukapheresis 2 (1.7%) 1(3.3%)
Others 5 (4.5%) 0 (0%)
ICU Interventions
Mechanical Ventilation 6 (5.2%) 0 (0%) <0.001 -
Mechanical Ventilation + Inotropes 2 (1.7%) 28 (93.3%)
Mechanical Ventilation + Inotropes + RRT 1 (0.9%) 0 (0%)
Inotropes 1 (0.9%) 0 (0%)
None 106 (91.4%) 2 (6.7%)
Laboratory Data
Hemoglobin (mg/dl) mean (+/- SD) 7.49 (+/-2.35) 7.26 (+/-2.51) 0.645 0.225
(-0.741-1.192)
WBCs (/cmm) median (IQR) 180 (130.8-293.7) 218 (123.2-350) 0.418 -
Platelets (/cmm) median (IQR) 31 (19-62) 22.5 (15-42.25) 0.092 - 
LDH (IU/L) median (IQR) 3158.5 (1740.5-5115) 4897 (1125-7100) 0.600 -
Uric Acid (mg/dl) median (IQR) 5.7 (3.9-8.36) 7.6 (4.5-15.05) 0.065 -
Potassium (meq/L) mean (+/- SD) 4.08 (+/-0.77) 3.85 (+/-0.68) 0.168 0.229
(-0.077-0.555)
Phosphorus (mg/dl) mean (+/- SD) 4.39 (+/-1.98) 3.9 (+/-2.15) 0.309 0.459
(0.431-1.351)
Calcium (mg/dl) mean (+/- SD) 8.9 (+/-0.89) 9.2 (+/-1.01) 0.176 -0.296
(-0.732-0.139)
Creatinine (mg/dl) median (IQR) 0.61 (0.5-0.8) 0.56 (0.43-0.9) 0.447 -
Complications
Respiratory 31 (26.7%) 18 (60%) 0.001 0.243
(0.105-0.562)
CNS 8 (6.9%) 6 (20%) 0.041 0.296
(0.094-0.933
Infectious 43 (37.1%) 23 (76.7%) <0.001 0.179
(0.071-0.453)
Renal 25 (21.6%) 7 (23.3%) 0.833 0.903
(0.347-2.345)
WBCs
100,000-200,000/cmm 66 (56.9%) 15 (50%) 0.541 1.320
>200,000/cmm 50 (43.1%) 15 (50%) (0.590-2.951)
ALL = Acute lymphoblastic Leukemia;   AML = Acute Myeloginous Leukemia;   CML = Chronic Myeloginous Leukemia;   CNS = Central Nervous System;   ICU = Intensive Care Unit;   RRT = Renal
Replacement Therapy;   WBC = White Blood Cells;   LDH = Lactate Dehydrogenase.
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was no mortality related to acute metabolic complications
or secondary to leukostasis in early phase of
cytoreduction. Many deaths in this study could have
been prevented by strict implementation of infection
control policy in hospital and prompt broad spectrum
antibiotics. 
Acute hyperleukocytic leukemia in children is not
uncommon and can be managed with appropriate
supportive care and monitoring. Most of the deaths were
related to sepsis during induction-remission phase of
chemotherapy instead of early complications of hyper-
leukocytosis.
REFERENCES
1. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM.
Hyperleukocytosis, leukostasis and leukapheresis: practice
management. Blood Rev 2012; 26:117-22.
2. Bakhshi S, Singh RB, Munot K, Pathania S. Complications of
"very high" leukocytosis in pediatric acute leukemia patients
managed without rasburicase and leukapheresis. Indian J
Pediatr 2014; 81:817-20.
3. Kong SG, Seo JH, Jun SE, Lee BK, Lim YT. Childhood acute
lymphoblastic leukemia with hyperleukocytosis at presentation.
Blood Res 2014; 49:29-35.
4. Kulkarni KP, Marwaha RK. Childhood acute lymphoblastic
leukemia with hyperleukocytosis at presentation: perspective
and lessons from a tertiary care institution in India. Asia Pac J
Clin Oncol 2011; 7:185-7.
5. Lowe EJ, Pui CH, Hancock ML, Geiger TL, Khan RB, Sandlund
JT. Early complications in children with acute lymphoblastic
leukemia presenting with hyperleukocytosis. Pediatr Blood
Cancer 2005; 45:10-5.
6. Mushtaq N, Fadoo Z, Naqvi A. Childhood acute lymphoblastic
leukaemia: experience from a single tertiary care facility of
Pakistan. J Pak Med Assoc 2013; 63:1399-404.
